Loading…
Loading…
Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota's Department of Chemistry to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, July 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (the "Company"), a clinical-stage biotechnology company developing therapeutics in based on carbohydrate chemistry, galectin antagonism, and oxygen transport, today announced the publication of a sponsored corporate research report by Globe Small Cap Research. The report Research Bioxytran as a multi-platform biotechnology story built around carbohydrate science, galectin antagonism, and oxygen-transport therapeutics, with active programs spanning antiviral therapy, stroke and hypoxia, and an emerging commercial bridge through the Company's A-SUQAR dietary supplement.
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25. The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the book introduces the concept of “Physiological Mapping,” a unique methodology designed to monitor tissue metabolism and oxygenation in vivo and in real-time.
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25.
Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 300 shares, a decrease of 97.1% from the February 26th total of 10,300 shares. Based on an average trading volume of 1,769,827 shares, the
Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the Company issued an aggregate of approximately 21,071,667 shares of its common stock at a purchase price of approximately $0.055 per share.
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and provided an update on the Company's planned Phase 3 registrational trial. The data, released March 2, 2026, were designed to establish the optimal dosing strategy and support advancement into a pivotal study intended to enable full regulatory approval.
BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2. The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile.